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A B S T R A C T
Objective: To examine associations of body mass index (BMI), subcutaneous fat area (SFA) and density (SFD),
visceral fat area (VFA) and density (VFD) and total psoas area (TPA) to outcomes among patients receiving
chemotherapy with or without bevacizumab for advanced or recurrent endometrial cancer (EC).
Methods: This was a multi-institutional, retrospective study of patients with EC treated with and without bev-
acizumab as part of front-line, platinum based chemotherapy. Demographics and clinical characteristics were
collected. SFA, VFA, SFD, VFD, and TPA were determined from pre-treatment CT scans using a deep learning
algorithm. Data was compared with overall survival (OS) and progression free survival (PFS).
Results: Seventy-eight patients were analyzed. The majority were Caucasian (87.2%) with a mean BMI of
34.7 kg/m2. PFS and OS did not differ between patients with BMI, SFA, VFA, SFD, VFD, or TPA≥ the 50th
percentile compared to<50th percentile (p= 0.91, 0.45, 0.71, 0.74, 0.60, and 0.74 respectively) and
(p=0.99, 0.59, 0.14, 0.77, and 0.85 respectively). When adjusting for prognostic factors, elevated VFA trended
towards shorter OS (25.1 vs 59.5months, HR=1.68 [0.92–3.05]).
Patients receiving bevacizumab had similar OS compared to those who did not (37.6 vs 44.5months,
p= 0.409). When stratified by adiposity markers, no subset demonstrated benefit from bevacizumab.
Conclusion: Obesity has been associated with increased levels of vascular endothelial growth factor (VEGF), the
main target for bevacizumab therapy. Imaging measurements of VFA may provide prognostic information for
patients with EC but no adiposity marker was predictive of improved response to bevacizumab.
1. Background
Obesity is a growing public health crisis, both nationally and in-
ternationally. The CDC estimates that approximately 39.8% percent of
US adults are obese (BMI > 30) and when considering women only,
this number approaches 45 percent (Ogden, 2017). Additionally, it is
estimated that 280,000 deaths were attributable to obesity and related
sequelae in 2015, making obesity the second most common cause of
preventable death in the United States (Ogden, 2017). Many of these
deaths are related to the subsequent development of malignancies, in-
cluding endometrial cancer. Arnold et al showed that endometrial
cancer was the second most common cancer among overweight and
obese women, accounting for approximately 107,000 cases worldwide
(Arnold et al., 2015). Aune et al also demonstrated that the relationship
between increasing BMI and endometrial cancer incidence is non-
linear, with a summary relative risk for a 5 unit increment in BMI of
1.54. A similar relationship exists between increasing BMI and mor-
tality (Aune et al., 2015).
There are three proposed mechanisms through which increased
adiposity is thought to contribute to the development of endometrial
cancer. The first is through aromatization of androgens in peripheral fat
leading to increased levels of bioavailable estrogen, promoting pro-
liferation and inhibiting apoptosis of endometrial cells. Secondly, obese
patients live in a state of chronic hyperinsulinemia which may actually
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promote tumor growth through multiple pathways. Elevated levels of
insulin decrease sex-hormone binding globulin (thus increasing bioa-
vailable estrogen) and lead to increases in bioavailable IGF1, which
functions at the cellular level as an anti-apoptotic and pro-angiogenic
factor. Insulin also acts directly on target cells as a growth factor
“primer” and anti-apoptotic agent. Thirdly, obesity promotes an in-
flammatory state, leading to increased levels of tumor necrosis factor
and interleukin-6, promoting tumor development (Renehan et al.,
2015). This obese and inflammatory state also contributes to tumor
growth through elevated circulating level of vascular endothelial
growth factor (VEGF) and angiopoietin-2 (ANGPT2) (Mick et al., 2002;
Silha et al., 2005). Additionally, this pro-inflammatory state may lead
to a catabolic effect on muscles which promotes decreased muscle mass
or sarcopenia (Stenholm et al., 2008).
Guiu et al demonstrated that, in patients with colorectal cancer,
those who were obese and treated with bevacizumab had poorer re-
sponse rates (RR), shorter PFS, and shorter OS (Guiu et al., 2010).
Treatment with antiangiogenic therapy has also been associated with
more dose limiting toxicities in patients with renal cell carcinoma
(Huillard et al., 2013). While anti-angiogenic therapies are not con-
sidered first line treatment in patients with endometrial cancer, there is
some data to support their use in advanced and recurrent disease
(Aghajanian et al., 2011, 2015; Lorusso et al., 2015).
While BMI is a useful population-level measure of obesity, data have
demonstrated that it is not the most precise marker of adiposity. Body
fat composition, as measured on dual-energy x-ray absorptiometry
(DXA) scanner, has been shown to have a complex relationship with
BMI that varies based on race, age, and gender (Mills et al., 2007). In
trying to identify more precise markers of adiposity and body fat
composition, additional data have supported the use of CT scan eva-
luation of subcutaneous and visceral fat areas as reproducible measures
of adiposity. These measures have been correlated with metabolic
syndrome and associated medical comorbidities (Fox et al., 2007;
Koster et al., 2010). To this end, we examined the association between
body mass index (BMI), subcutaneous fat area (SFA), visceral fat area
(VFA), subcutaneous fat density (SFD), visceral fat density (SFD), and
total psoas area (TPA) to outcomes in patients treated with and without
first-line bevacizumab-based chemotherapy for advanced and recurrent
endometrial cancer.
2. Methods
This is a multi-institutional, IRB approved, retrospective cohort
study of patients with advanced (stage III-IV) and recurrent endometrial
cancer. Any woman diagnosed between 2006 and 2012 was evaluated.
Patients were dichotomized based on whether treatment incorporated
frontline bevacizumab. Demographics, physical exam parameters, sur-
gical data, and tumor characteristics were collected.
To assess a patient’s adiposity, SFA, VFA, SFD, and VFD were cal-
culated from pre-treatment CT scans at L3 using a computer-aided de-
tection scheme. The scheme first applies a convolution neural network
based deep learning algorithm to automatically detect abdominal re-
gion of interest depicting on all CT image slices scanned from one pa-
tient and then segment human body depicting on each CT image into
three categories of SFA, VFA and other non-fat related human organs or
tissues. The fat density threshold is within −140 HU to −40 HU of CT
values and total psoas area is within −30–110 HU of CT values (Peng
et al., 2012). After segmentation, the scheme computed the cross-sec-
tional size of SFA and VFA, as well as two average density values of two
fat areas (SFD and VFD), in each CT slide. By combining the compu-
tation results of all involved CT slides in the abdominal region, the
volume of SFA and VFA, and overall density of SFD and VFD of each
patient are computed and recorded. The details of this computer-as-
sisted image process and feature computation method have been pre-
viously reported (Wang et al., 2017). As no “normal” value has been
established for any of these markers of adiposity or sarcopenia, patients
were dichotomized based on the median. These computed features
(SFA, VFA, SFD, VFD, and TPA) were compared with survival data,
including overall survival (OS) and progression free survival (PFS).
Specifically, each biomarker was dichotomized at the median into
“upper 50%” and “lower 50%” strata, then OS and PFS were depicted
within strata using the Kaplan-Meier product-limit method, and com-
pared using the log-rank test (for unadjusted results) and Cox propor-
tional-hazards models adjusted for age, stage, and residual disease. SAS
9.3 and R 3.5.1 were used for statistical analyses.
3. Results
A total of 78 patients were analyzed in this study. The majority were
Caucasian with a mean BMI of 34.7 kg/m2. Stage III disease accounted
for 43.6% of cases while 39.7% had stage IV disease and 16.7% had
recurrent disease. The median SFA was 326.1 cm2 and median VFA was
174.8 cm2. Median SFD and VFD in this population was −95.1 HU and
−79.4 HU, respectively. Median TPA was 15 cm2 (Table 1). There was
no significant difference in patient demographics or adiposity markers
when patients were dichotomized by treatment with or without bev-
acizumab. Additionally, those who received platinum/taxane based
chemotherapy with bevacizumab vs. platinum/taxane based che-
motherapy alone had similar OS (37.6 vs 44.5months, p= 0.41).
When patients were dichotomized by BMI (≥50th percentile vs<
Table 1
Patient demographics.
Variable Count (%) or Mean ± SD
Total number of patients 78
Age at start of chemo 61.5 ± 9.5
Race
Caucasian 68 (87.2%)
Black 8 (10.3%)
Other 2 (2.5%)
Weight (kg) 92.0 ± 26.4
Height (cm) 162.1 ± 6.1
BMI (kg/m2) 34.7 ± 9.4
Stage
III 34 (43.6%)
IV 31 (39.7%)
Recurrent 13 (16.7%)
Residual disease
No 45 (57.7%)
Yes 33 (42.3%)
Histology
Serous 17 (21.8%)
Endometrioid 54 (69.2%)
Clear cell 3 (3.9%)
Other 4 (5.1%)
Regimen
Paclitaxel/Carboplatin 26 (33.3%)
Paclitaxel/Carboplatin/Bevacizumab 33 (42.3%)
Ixabepilone/Carboplatin/Bevacizumab 15 (19.2%)
Other 4 (5.2%)
Best response
Partial remission 14 (18.0%)
Complete remission 38 (48.7%)
Stable disease 9 (11.5%)
Progressive disease 7 (9.0%)
Not measurable 10 (12.8%)
Computed SFA 326.1 ± 163.8
Computed VFA 174.8 ± 88.6
Computed SFD −95.1 ± 9.3
Computed VFD −79.4 ± 27.9
Computed TPA 15.0 ± 7.0
Follow-up time (mo) 45.1 ± 31.5
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50th percentile), there was no significant difference in PFS (21.8 vs
25.3 months, p=0.91). The same was true for both SFA and VFA (42.3
vs 24.1months, p=0.45 and 21.8 vs 25.6months, p= 0.71).
Additionally, when comparing SFD and VFD dichotomized by the
median, no significant difference was noted in PFS (25.3 vs
24.1 months, p=0.74 and 24.1 vs 42.3 months, p=0.60). When si-
milarly dichotomized by TPA, there was no difference in PFS either
(21.8 vs 25.3 months, p=0.74). When controlling for prognostic fac-
tors such as age, stage, and residual disease, no statistically significant
difference was noted among adiposity or sarcopenia markers and on-
cologic outcome (Table 2).
No difference in OS was noted when patients were dichotomized by
BMI (≥50th percentile vs< 50th percentile (41.8 vs 38.4months,
p=0.99). SFA and VFA were also not associated with a significant
difference in OS (26.2 vs 53.8 months, p=0.59 and 25.1 vs
59.5 months, p=0.14). Neither SFD, VFD, nor TPA demonstrated a
difference (31.5 vs 38.4months, p=0.77; 34.1 vs 43.2months,
p=0.85; 33.3 vs 43.2 months, p=0.87) either. However, when ad-
justing for prognostic factors, increased VFA was associated with a
trend toward shorter OS (HR 1.68, [0.92–3.05], p=0.09) (Fig. 1). The
remaining markers of adiposity continued to demonstrate no significant
difference. After adjustment for prognostic factors and stratification by
treatment regimen (treated with or without bevacizumab), no markers
of adiposity or sarcopenia were associated with differences in outcomes
(Table 3).
4. Discussion
The prevalence of obesity continues to rise, and the Center for
Disease Control projects that 50% of American adults will be obese by
2030 (CDC Overweight and Obesity, 2019). Increasing weight and
obesity is associated with the development of endometrial cancer
through increased aromatization of androgens in peripheral fat cells,
chronic hyperinsulinemia and subsequent reduction in circulating sex
hormone binding globulin, and promotion of a pro-inflammatory state
(Renehan et al., 2015). While obesity has certainly been linked to the
development of endometrial cancer, there is conflicting data about its
relationship, as measured by BMI, to patient outcomes (Greenlee et al.,
2017). Growing data suggest that not just obesity, but body composi-
tion and fat distribution, may be an important determinant in outcomes
in cancer patients (Strulov Shachar and Williams, 2017).
Obesity has also been associated with increased circulating levels of
vascular endothelial growth factor (VEGF) (Silha et al., 2005). This
might imply that treatment in obese patients with bevacizumab, a
monoclonal antibody that inhibits angiogenesis through blockade of
VEGF-A, would provide improvement in outcomes among obese in-
dividuals. In the colorectal literature, however, worse outcomes have
been demonstrated with the use of bevacizumab in patients with an
elevated BMI, SFA, and/or VFA (Guiu et al., 2010). Antiangiogenic
therapy in patients with renal cell carcinoma has also been associated
with adverse outcomes, in particular an increase in dose limiting toxi-
cities (Huillard et al., 2013).
Data from Gynecologic Oncology Group (GOG) protocol 86P has
demonstrated that, in advanced or recurrent endometrial cancer, the
addition of bevacizumab did not improve PFS, at least in comparison to
the selected historical control, but did appear to influence OS. This was
not, however, a pre-specified endpoint and is hypothesis generating
only (Aghajanian et al., 2015.). MITO End-2, which was a randomized,
phase 2 trial that evaluated the addition of bevacizumab to carbo-
platin/paclitaxel in advanced and recurrent endometrial cancer, noted
a significant improvement in PFS (13 vs 8.7months) with the addition
of bevacizumab (Lorusso et al., 2015).
Our study evaluated patients with advanced and recurrent en-
dometrial cancer who underwent therapy with platinum/taxane che-
motherapy with or without bevacizumab and found that no marker of
adiposity (BMI, SFA, VFA, SFD, VFD) or sarcopenia was significantly
associated with survival outcomes. Increased visceral fat area, however,
did suggest a trend toward shorter OS, though this was independent of
treatment with bevacizumab. This may indicate that elevated VFA is a
negative prognostic biomarker for this population, the knowledge of
which may, in the future, identify patients at high risk for treatment
failure for whom novel treatment strategies may be indicated. This
would require validation in a larger study. The limitations of this study
include the retrospective nature of the data collection, small patient
numbers, and potential bias in terms of patient selection in that bev-
acizumab is not currently indicated as a part of front line therapy so
those patients included here may have received bevacizumab as part of
clinical trials or off label and may not be representative of the popu-
lation as a whole.
Patients with advanced and recurrent endometrial cancer tradi-
tionally have poor outcomes, with an average OS of approximately
12months. Novel therapeutic regimens are necessary to improve sur-
vival in these women. Imaging biomarkers may provide a modality to
Table 2
Unadjusted and adjusted progression free survival.
Variable Lower 50%
Median PFS (mo.)
Upper 50%
Median PFS (mo.)
p-valuea Hazard ratio p-valueb
BMI (kg/m2) 25.6 [11.7, 46.7] 42.3 [10.6, –] 0.91 1.36 [0.79, 2.35] 0.26
SFA (cm2) 24.1 [12.3, –] 42.3 [14.6, –] 0.45 0.88 [0.46, 1.69] 0.70
VFA (cm2) 25.6 [15.2, –] 21.8 [12.7, –] 0.71 0.97 [0.51, 1.87] 0.93
SFD (HU) 24.1 [17.2, –] 25.3 [11.7, –] 0.74 1.20 [0.65, 2.20] 0.56
VFD (HU) 42.3 [11.6, –] 24.1 [14.6, 51.3] 0.60 1.24 [0.65, 2.38] 0.52
Psoas (cm2) 25.3 [15.2, 50.4] 21.8 [11.6, –] 0.74 1.09 [0.53, 2.27] 0.81
Numbers within brackets represent 95% confidence limits (with “–” indicating no estimable upper limit).
a Log-rank test (unadjusted).
b Cox proportional-hazards model (adjusted for age, stage, and residual disease).
Fig. 1. Adjusted overall survival based on visceral fat area.
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improve tailored therapies and further investigation in this field is
warranted.
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Table 3
Unadjusted and adjusted overall survival.
Variable Lower 50%
Median OS (mo.)
Upper 50%
Median OS (mo.)
p-valuea Hazard ratio p-valueb
BMI (kg/m2) 38.4 [25.4, 79.7] 41.8 [23.9, 88.8] 0.99 1.48 [0.88, 2.48] 0.13
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SFD (HU) 38.4 [31.9, 75.2] 31.5 [22.2, –] 0.77 0.88 [0.49, 1.60] 0.68
VFD (HU) 43.2 [25.1, –] 34.1 [23.2, 79.7] 0.85 1.05 [0.56, 1.98] 0.89
Psoas (cm2) 43.2 [26.2, –] 33.3 [21.3, –] 0.87 1.83 [0.34, 1.72] 0.09
Numbers within brackets represent 95% confidence limits (with “–” indicating no estimable upper limit).
a Log-rank test (unadjusted).
b Cox proportional-hazards model (adjusted for age, stage, and residual disease).
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